The biotechnology company behind the troubled Alzheimer’s drug aducanumab has been embroiled in a fresh round of controversy following the long-awaited release of results from two pivotal studies.

Last week, the US-based company Biogen published data from the phase III trials in a lesser-known medical journal — The Journal of Prevention of Alzheimer’s Disease — whose editor-in-chief Dr Paul Aisen was a co-author of the studies.

Dr Aisen said he was not involved in the review of the research or the decision to publish, details of which are listed in the disclosure section of the papers.

Biogen had been under increasing pressure to allow the wider scientific community to review the data that had led the Food and Drug Administration (FDA) to grant accelerated approval for aducanumab (Aduhelm) last June.